Proteasome Inhibitors

Proteasome Inhibitors

Proteasome inhibitors constitute a drug class employed in the treatment of certain blood cancers, notably multiple myeloma and mantle cell lymphoma. These inhibitors disrupt the normal protein degradation process in cancer cells by interfering with proteasomes, and cellular structures responsible for breaking down proteins. Consequently, the accumulation of proteins occurs, leading to cell death. The proteasome inhibitor market has seen steady growth in recent years due to several factors, such as increasing incidence of cancer, rising research & development activities, increasing awareness and diagnosis of cancer, rising healthcare expenditure, rising regulatory support, and surge in company collaborations & partnerships are leading drivers of proteasome inhibitors globally.

The Proteasome Inhibitors Market is expected to grow at a steady rate of around 8.01% owing to the increasing geriatric population. As the aging population grows, the prevalence of multiple myeloma is expected to rise. For instance, in February 2021, according to the Frontiers, the prevalence of multiple myeloma is projected to rise substantially at an estimated 80% per year in the next 20 years because of an aging population. Several factors, including a surge in the incidence of pancreatic cancer, increasing awareness regarding cancer, and increased investments in oncology departments are driving the market's growth during the forecast period. Apart from this, accelerated treatment efficiency with proteasome inhibitors has resulted in faster treatment procedures and better accuracy which is also driving this market of proteasome inhibitors at a steady rate.

• Based on the mode of administration, the market is segmented into oral, intravenous, and others. The oral segment held the maximum share in the global market of proteasome inhibitors in 2022 owing to the rising demand for oral drugs among patients. Tablets are reported to be the most consumed solid dosage forms among all medication forms, because of their highly effective composition, and ease of consumption. The oral mode of drug administration is much more convenient and easier on pockets for the consumers which is boosting this segment’s growth. Thus, among the modes of administration, the oral segment held a significant share of the market in 2022.
• Based on indication, the market is categorized into mantle cell lymphoma, multiple myeloma, and others. The mantle cell lymphoma segment is expected to hold a significant share of the market in the forecast period owing to the rising prevalence of mantle cell lymphoma. For instance, in July 2023, according to the National Library of Medicine, mantle cell lymphoma (MCL) had an annual incidence of one case per 200,000 people. MCL is more common in men (3 to 1), and the median age at diagnosis usually ranges from 60 to 70 years old. Mantle cell lymphoma is a type of non-Hodgkin lymphoma, a cancer that originates in the lymphocytes. It specifically affects B cells and often involves the lymph nodes, spleen, bone marrow, and blood. Mantle cell lymphoma is known for its aggressive nature. Thus, amongst indications, the mantle cell lymphoma category is expected to witness a higher CAGR during the forecast period.
• For a better understanding of the market adoption of proteasome inhibitors, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the increasing geriatric population, and rising number of investments in developing effective proteasome inhibitors. Government organizations are initiating cancer awareness programs for the sake of the growing rate of cancer cases in the region. For instance, according to the American Cancer Society, about 35,780 new multiple myeloma cases will be diagnosed (19,520 in men and 16,260 in women) in the U.S. in the year 2024. Thus, amongst regions, North America held a significant share of the market in 2022.
• Some of the major players operating in the market include AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; Takeda Pharmaceutical Company Limited; TG Therapeutics; Pfizer Inc.; QLi5 Therapeutics GmbH; Baxter; GSK plc.; Kezar Life Sciences Inc.